Early Mortality in a Multinational Systemic Sclerosis Inception Cohort
Objective To determine mortality and causes of death in a multinational inception cohort of subjects with systemic sclerosis (SSc). Methods We quantified mortality as standardized mortality ratio (SMR), years of life lost, and percentage mortality in the first decade of disease. The inception cohort...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 69; no. 5; pp. 1067 - 1077 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.05.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
To determine mortality and causes of death in a multinational inception cohort of subjects with systemic sclerosis (SSc).
Methods
We quantified mortality as standardized mortality ratio (SMR), years of life lost, and percentage mortality in the first decade of disease. The inception cohort comprised subjects recruited within 4 years of disease onset. For comparison, we used a prevalent cohort, which included all subjects irrespective of disease duration at recruitment. We determined a single primary cause of death (SSc related or non–SSc related) using a standardized case report form, and we evaluated predictors of mortality using multivariable Cox regression.
Results
In the inception cohort of 1,070 subjects, there were 140 deaths (13%) over a median follow‐up of 3.0 years (interquartile range 1.0–5.1 years), with a pooled SMR of 4.06 (95% confidence interval [95% CI] 3.39–4.85), up to 22.4 years of life lost in women and up to 26.0 years of life lost in men, and mortality in the diffuse disease subtype of 24.2% at 8 years. In the prevalent cohort of 3,218 subjects, the pooled SMR was lower at 3.39 (95% CI 3.06–3.71). In the inception cohort, 62.1% of the primary causes of death were SSc related. Malignancy, sepsis, cerebrovascular disease, and ischemic heart disease were the most common non–SSc‐related causes of death. Predictors of early mortality included male sex, older age at disease onset, diffuse disease subtype, pulmonary arterial hypertension, and renal crisis.
Conclusion
Early mortality in SSc is substantial, and prevalent cohorts underestimate mortality in SSc by failing to capture early deaths, particularly in men and those with diffuse disease. |
---|---|
Bibliography: | Supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia, and Pfizer. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Scleroderma Society of Saskatchewan, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics, Inc., Dr. Fooke Laboratorien GmbH, Euroimmun, Mikrogen GmbH, Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and Jewish General Hospital and Lady Davis Research Institute, Montreal, Quebec, Canada. The CSRG has also received educational grants from Pfizer and Actelion Pharmaceuticals. The Madrid University Hospital 12 de Octubre Scleroderma Cohort Study was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (FIS grant PI11/0156). Dr. Nikpour's work was supported by the National Health and Medical Research Council of Australia (fellowship APP1071735). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ISSN: | 2326-5191 2326-5205 |
DOI: | 10.1002/art.40027 |